Publications

Filtrer par

Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study
Effect of liraglutide therapy on liver fat content in patients with inadequately controlled type 2 diabetes. The Lira-NAFLD study
J Clin Endocrinol Metab
2016 Oct

Petit, J. M.
Cercueil, J. P.
Loffroy, R.
Denimal, D.
Bouillet, B.
Fourmont, C.
Chevallier, O.
Duvillard, L.
Verges, B.

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is very frequent in type 2 diabetes with increased risk of further development of liver fibrosis. Animal studies have shown that GLP-1 receptor agonists may reduce liver lipogenesis. However, data in humans are scarce. OBJECTIVE: To study the effect of liraglutide 1.2 mg/d on liver fat content (LFC) in patients with uncontrolled type 2 diabetes and to evaluate the factors potentially associated with liraglutide-induced modification of LFC. METHODS: LFC was measured by 1H-MR spectroscopy before and after 6 months of liraglutide treatment in 68 patients with uncontrolled type 2 diabetes mellitus. RESULTS: Treatment with liraglutide was associated with a significant decrease in body weight, HbA1C and a marked relative reduction in LFC of 31% (p<0.0001). No significant modification of LFC was observed in a parallel group of patients 6 months after intensification of the antidiabetic treatment with insulin. The reduction in LFC and body weight were highly correlated (r= 0.490, p<0.0001). In multivariate analysis, the reduction in LFC was independently associated with baseline LFC (p<0.0001), age (p=0.010) and with reduction in body weight, (p<0.0001), triglycerides (p=0.019) and HbA1c (p=0.034). In the patients who had no significant decrease in body weight, no significant reduction in LFC was observed. CONCLUSIONS: Six months of treatment with liraglutide 1.2 mg/d significantly reduced LFC in patients with inadequately controlled type 2 diabetes and this effect was mainly driven by body weight reduction. Further studies are needed to confirm that this reduction in LFC may significantly reduce fibrosis progression.

Voir plus - Pubmed
Size dependent skin penetration of nanoparticles in murine and porcine dermatitis models
Size dependent skin penetration of nanoparticles in murine and porcine dermatitis models
Eur J Pharm Biopharm
2016 Mar

Try, C.
Moulari, B.
Beduneau, A.
Fantini, O.
Pin, D.
Pellequer, Y.
Lamprecht, A.

A major limitation in the current topical treatment of inflammatory skin diseases is the inability to selectively deliver the drug to the inflammation site. Recently, smart drug delivery systems such as nanocarriers are being investigated to enhance the selective deposition of anti-inflammatory drugs in inflamed areas of the skin to achieve higher therapeutic efficacy with minimal side effects. Of such systems, polymeric nanoparticles are considered very efficient carriers for the topical drug delivery. In the current work, poly(l-lactide-co-glycolide) nanoparticles of nominal sizes of 70nm (NP70) and 300nm (NP300) were studied for their intra-epidermal distribution in murine and pig atopic dermatitis models over time against the respective healthy controls. Confocal laser scanning microscopical examination of skin biopsies was utilized for the qualitative and semi-quantitative analyses of nanoparticles skin deposition and penetration depth. While no skin penetration was found for any of the particles in healthy skin, the accumulation of NP70 was significantly higher than NP300 in inflamed skin (15-fold in mice, 5-fold in pigs). Penetration depth of NP70 decreased over time in mice from 55+/-3mum to 20+/-2mum and similar tendencies were observed for the other formulations. In inflamed pig skin, a similar trend was found for the penetration depth (NP70: 46+/-12mum versus NP300: 23+/-3mum); however, the NP amount remained constant for the whole analyzed period. Their ability to penetrate specifically into inflamed skin combined with minimal effects on healthy skin underlines small polymeric nanoparticles' potential as selective drug carriers in future treatment of chronic inflammatory skin diseases such as atopic dermatitis.

Voir plus - Pubmed
ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity
ApoA-II HDL Catabolism and Its Relationships With the Kinetics of ApoA-I HDL and of VLDL1, in Abdominal Obesity
J Clin Endocrinol Metab
2016 Apr

Verges, B.
Adiels, M.
Boren, J.
Barrett, P. H.
Watts, G. F.
Chan, D.
Duvillard, L.
Soderlund, S.
Matikainen, N.
Kahri, J.
Lundbom, N.
Lundbom, J.
Hakkarainen, A.
Aho, S.
Simoneau-Robin, I.
Taskinen, M. R.

We study the associations between apoA-II fractional catabolic rate (FCR) and the kinetics of VLDL subspecies and apoA-I and show that, in abdominally obese individuals, apoA-II FCR is positively and independently associated with both apoA-I FCR and VLDL1-TG indirect FCR.

Voir plus - Pubmed
Biorelevant media resistant co-culture model mimicking permeability of human intestine
Biorelevant media resistant co-culture model mimicking permeability of human intestine
Int J Pharm
15 mars 2015

Antoine, D.
Pellequer, Y.
Tempesta, C.
Lorscheidt, S.
Kettel, B.
Tamaddon, L.
Jannin, V.
Demarne, F.
Lamprecht, A.
Beduneau, A.

Voir plus - Pubmed
Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility
Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility
Oncogene
19 février 2015

Edmond, V.
Dufour, F.
Poiroux, G.
Shoji, K.
Malleter, M.
Fouque, A.
Tauzin, S.
Rimokh, R.
Sergent, O.
Penna, A.
Dupuy, A.
Levade, T.
Theret, N.
Micheau, O.
Segui, B.
Legembre, P.

Voir plus - Pubmed
Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion
Hyperthermia restores apoptosis induced by death receptors through aggregation-induced c-FLIP cytosolic depletion
Cell death & disease

Morle, A.
Garrido, C.
Micheau, O.

Voir plus - Pubmed
Nanovectorization of TRAIL with Single Wall Carbon Nanotubes Enhances Tumor Cell Killing
Nanovectorization of TRAIL with Single Wall Carbon Nanotubes Enhances Tumor Cell Killing
Nano Lett
11 février 2015

Zakaria, A. B.
Picaud, F.
Rattier, T.
Pudlo, M.
Saviot, L.
Chassagnon, R.
Lherminier, J.
Gharbi, T.
Micheau, O.
Herlem, G.

Voir plus - Pubmed
Antifibrotic role of alphaB-crystallin inhibition in pleural and subpleural fibrosis
Antifibrotic role of alphaB-crystallin inhibition in pleural and subpleural fibrosis
Am J Respir Cell Mol Biol
fevrier 2015

Bellaye, P. S.
Burgy, O.
Colas, J.
Fabre, A.
Marchal-Somme, J.
Crestani, B.
Kolb, M.
Camus, P.
Garrido, C.
Bonniaud, P.

Voir plus - Pubmed
Ion milling coupled field emission scanning electron microscopy reveals current misunderstanding of morphology of polymeric nanoparticles
Ion milling coupled field emission scanning electron microscopy reveals current misunderstanding of morphology of polymeric nanoparticles
Eur J Pharm Biopharm
18 nov 2014

Francis, D. Moufta, S. Steffen, R. Beduneau, A. Pellequer, Y. Lamprecht, A.

Voir plus - Pubmed
Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Patients
Prospective Study of the Evolution of Blood Lymphoid Immune Parameters during Dacarbazine Chemotherapy in Metastatic and Locally Advanced Melanoma Patients
PLoS One
August 2014

Mignot, G. Hervieu, A. Vabres, P. Dalac, S. Jeudy, G. Bel, B. Apetoh, L. Ghiringhelli, F.

Voir plus - Pubmed

Pages